Biotech stocks have long enticed investors with the promise of outsized gains. Amid recent federal policy shifts, two previously under-the-radar names are catching attention.
Last week, Health and Human Services Secretary Robert F. Kennedy Jr. announced plans to fast-track rare-disease drug approvals and promised a less cumbersome regulatory framework. That announcement aims to cement the U.S. as the global center of biotech innovation, which sent gene therapy shares sharply higher.
